The human intestinal tract is inhabited by 10-100 trillion microbes consisting of thousands of different species that have co-evolved with the human host. This microbial community, termed the gut microbiota, has an immense capacity to affect host biology.
It is fundamental to many processes, including development of our immune system, processing of otherwise indigestible dietary polysaccharides, and production of vitamins and hormones. However, increasing evidence indicates that perturbations of the gut microbiota contribute to a range of diseases, including obesity and cardiometabolic diseases.
Latest updatesNews archive
Courses & events
18 September 2022
Annika Wahlström was invited to speak on Microbiota and Metabolism at the Europhysiology 2022
We take a translational approach to investigate the role of the gut microbiota in cardiometabolic diseases, focusing on diabetes, hepatic steatosis, atherosclerosis, and heart failure.
By identifying associations between gut bacteria and/or their metabolites and cardiometabolic markers in large population-based cohort studies, we generate hypotheses that could explain how the microbiota contributes to metabolic diseases.
Our hypotheses are tested using a variety of tools, including gnotobiotic mice, primary cell culture, and bioreactors to establish causality and determine the underlying molecular mechanisms.
Words describing the culture in our lab.
Our team has co-authored a large number of highly impactful original research and literature review articles.
Dynamics of the normal gut microbiota: A longitudinal one-year population study in Sweden
Article, Cell Host & Microbe, April 28, 2022
The metabolic role and therapeutic potential of the microbiome
Review article, Endocrine Reviews, 30 January 2022
Feeding diversified protein sources exacerbates hepatic insulin resistance via increased gut microbial branched-chain fatty acids and mTORC1 signaling in obese mice
Article in Nature Communications, June 7, 2021
Our laboratory’s location, within Sahlgrenska University Hospital, provides unique opportunities to engage with clinicians and study participants and pursue basic and translational research.
To achieve our overarching aim of improving human health by targeting the gut microbiota, we have developed a research group comprising experts in microbiology, molecular biology, biochemistry, metabolomics, proteomics, epigenetics, physiology, bioinformatics, and medicine from around the world.